Onconova Therapeutics, Inc.: Revision history

20 August 2022

• curprev 11:2311:23, 20 August 2022 95.149.241.133 talk 1,238 bytes +11 No edit summary undo

13 August 2022

• curprev 16:5216:52, 13 August 2022 109.180.50.163 talk 1,227 bytes +15 No edit summary undo

30 July 2022

• curprev 17:0617:06, 30 July 2022 >Chris 1,212 bytes +1,212 Created page with "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is i..."